Clinical update: In its Nov 3 filing, Arvinas said enrollment in the phase 1 ARV-806 monotherapy dose escalation was complete. Data in advanced KRAS G12D-mutant solid tumors are planned for Q4 2026; this is not an efficacy result.
arvinas.gcs-web.com/static-f…
1
Trial watch: Phase 1 ONKORAS-101, started in 2024, studies BBO-8520 alone and in combinations for unresectable locally advanced or metastatic KRAS G12C-mutant NSCLC. Safety and early activity are being assessed; this is not an efficacy result.
clinicaltrials.ucsd.edu/tria…
3
Trial watch: A separate phase 1 study begun in 2026 (NCT07535112) evaluates BAY 3771249 alone or with cetuximab in advanced KRAS G12D-mutant colorectal cancer. Safety and early antitumor activity are under study; this is not an efficacy result.
clinicaltrials.bayer.com/stu…
3
Trial watch: Started in 2024, a first-in-human phase 1/2 study evaluates investigational KRAS G12D inhibitor TSN1611 in advanced solid tumors with that mutation. It studies safety, tolerability and early activity; the design is not an efficacy result.
cancer.gov/research/particip…
1
Trial watch: Started in 2024, a first-in-human phase 1/2 study evaluates GDC-7035 alone and with other treatments in advanced KRAS G12D-mutant solid tumors. It examines safety, drug exposure and early activity; the design is not an efficacy result.
clinicaltrials.ucsd.edu/tria…
4
Trial watch: Started in 2025, a phase 1a study evaluates KQB548 in KRAS G12D-mutant locally advanced or metastatic pancreatic, colorectal and non-small cell lung cancers. It studies safety, dose and activity; trial design is not an efficacy result.
clinicaltrials.ucsd.edu/tria…
3
Trial watch: Launched in 2024, phase 1/2 PROSPER evaluates FMC-376 alone or with pembrolizumab in advanced solid tumors with KRAS G12C mutations. The study includes dose escalation and expansion; its design is not an efficacy result.
cancer.gov/research/particip…
2
Trial watch: Started in 2025, phase 1 MK-4716-001 assesses safety alone or in combinations. Cohorts include KRAS-altered advanced tumors; the pembrolizumab arm enrolls untreated metastatic NSCLC with KRAS alterations. This is a trial design.
cancer.gov/research/particip…
3
Trial watch: Started in 2025, a phase 1/1b study evaluates AMG 410 alone or with other agents in advanced KRAS-altered solid tumors. It examines safety, dosing and preliminary activity; the trial design does not establish clinical benefit.
clinicaltrials.gov/study/NCT…
6
Trial watch: Launched in 2025, phase 1 KONQUER-101 studies pan-KRAS inhibitor BBO-11818 alone and in combinations for selected advanced KRAS-mutant solid tumors. It assesses safety and preliminary activity; the study design is not proof of benefit.
cancer.gov/research/particip…
6
Trial archive: Registered in 2024, a phase 1 study was designed to assess pan-KRAS inhibitor BGB-53038 alone or in combinations for selected advanced KRAS-altered solid tumors. NCI now lists it as administratively complete; this is not an efficacy result.
cancer.gov/research/particip…
8
Trial watch: KST-6051 is in a first-in-human phase 1 study, alone or with other anticancer agents, for advanced KRAS-mutant solid tumors. Dose escalation and expansion assess safety and tolerability; efficacy remains under study.
cancer.gov/research/particip…
6
Trial watch: VS-7375-203 is a separate phase 2 study evaluating VS-7375 alone and in combinations for KRAS G12D-mutant metastatic colorectal cancer. It includes cohorts with different prior treatment histories; safety and efficacy remain under study. cancer.gov/research/particip…
6
Trial watch: A separate phase 2 study (VS-7375-202) is evaluating VS-7375 alone or with cetuximab in previously treated KRAS G12D-mutant advanced NSCLC. Safety and efficacy are under study. cancer.gov/research/particip…
6
Trial watch: BLU-924 (SAR449336), an investigational pan-KRAS inhibitor, is being studied in a phase 1/2 trial in selected metastatic KRAS-mutant pancreatic, lung and colorectal cancers. Safety and antitumor activity are under study. cancer.gov/research/particip…
6
Trial watch: Started in 2024, a phase 1 study evaluates KRAS G12D-targeting TCR-engineered T cells in previously treated advanced solid tumors with selected HLA types. Recruitment is complete; safety and activity are under study. astrazenecaclinicaltrials.co…
4
Trial watch: A phase 3 study compares chemotherapy with or without panitumumab in previously treated, unresectable or metastatic pancreatic cancer with KRAS wild type and no BRAF V600E mutation. Efficacy remains under study. cancer.gov/research/particip…
4
Trial watch: A phase 1 study tests pre-surgery mFOLFIRINOX plus KRAS vaccine ELI-002 7P, with or without tislelizumab, in resectable or borderline resectable KRAS-mutant pancreatic cancer. Safety is the primary focus; results are pending. cancer.gov/research/particip…
5
Trial watch: A phase 1/2 study is testing sotorasib plus trastuzumab deruxtecan in previously treated, advanced KRAS G12C-mutant NSCLC. It examines safety, dose and preliminary activity; clinical benefit remains under study. cancer.gov/research/particip…
4
Trial watch: AN9025, an investigational oral pan-RAS(ON) inhibitor, is in a first-in-human phase 1 study of advanced RAS-mutant solid tumors. Dose escalation and expansion assess safety and preliminary activity; this is a trial design, not a result. cancer.gov/research/particip…
2
